Payments – Talk Bio

Takeda and Innovent Forge $1.2B Upfront Oncology Pact for Bispecific and ADC Therapies, Total Deal Valued Up to $11.4B

4 days ago talkbio0Tagged Antibodies, Bispecific, Antibody-Drug Conjugates, Cancer Therapeutic Procedure, co-development, global strategic partnership, IBI343, IBI363, Innovent Biologics, Neoplasms, Payments, Takeda

Takeda; Innovent Biologics; global strategic partnership; bispecific antibody; antibody-drug conjugate (ADC); oncology; IBI363; IBI343; IBI3001; $1.2 billion upfront; $11.4 billion total deal; cancer therapy; co-development; milestone payments

Novo throws weight behind budding rare disease pipeline

1 week ago talkbio0Tagged complement system, MASP-3 Inhibitor, Novo Nordisk, Omeros, Paroxysmal nocturnal hemoglobinuria, Payments, pipeline, Rare Diseases, Zaltenibart

Novo Nordisk; rare disease; pipeline; Omeros; Zaltenibart; MASP-3 inhibitor; PNH; complement system; milestone payments

Healthcare Sector Winners and Losers in the 2024 Government Funding Bill

10 months ago talkbio0Tagged Government, Health care facility, hospital-at-home programs, Legislation, Medicaid, Medicare, pay, Payments, Physicians, shutdown, Symmetrical dyschromatosis of extremities, Telemedicine

Healthcare funding, government shutdown, telehealth, Medicare payments, Medicaid DSH, hospital-at-home programs, physician pay cuts, healthcare legislation.

CMS Approves Transitional Pass-Through Payments for Renal Denervation Systems from Medtronic and Recor Medical

12 months ago talkbio0Tagged Hypertensive disease, Medtronic, Myasthenic Syndromes, Congenital, Payments, Recor Medical, Renal Denervation Systems, Transitional cell morphology

Renal Denervation Systems, CMS, Transitional Pass-Through Payments, Medtronic, Recor Medical, Hypertension Treatment